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Abstract
Copper, an essential trace element acquired through nutrition, is an important co-factor for pro-angiogenic factors
including vascular endothelial growth factor (VEGF). Decreasing bioavailable copper has been used as an anti-
angiogenic and anti-cancer strategy with promising results. However, the role of copper and its potential as a therapy
in mesothelioma is not yet well understood. Therefore, we monitored copper levels in progressing murine
mesothelioma tumors and analyzed the effects of lowering bioavailable copper. Copper levels in tumors and organs
were assayed using atomic absorption spectrophotometry. Mesothelioma tumors rapidly sequestered copper at early
stages of development, the copper was then dispersed throughout growing tumor tissues. These data imply that
copper uptake may play an important role in early tumor development. Lowering bioavailable copper using the
copper chelators, penicillamine, trientine or tetrathiomolybdate, slowed in vivo mesothelioma growth but did not
provide any cures similar to using cisplatin chemotherapy or anti-VEGF receptor antibody therapy. The impact of
copper lowering on tumor blood vessels and tumor infiltrating T cells was measured using flow cytometry and
confocal microscopy. Copper lowering was associated with reduced tumor vessel diameter, reduced endothelial cell
proliferation (reduced Ki67 expression) and lower surface ICAM/CD54 expression implying reduced endothelial cell
activation, in a process similar to endothelial normalization. Copper lowering was also associated with a CD4+ T cell
infiltrate. In conclusion, these data suggest copper lowering is a potentially useful anti-mesothelioma treatment
strategy that slows tumor growth to provide a window of opportunity for inclusion of other treatment modalities to
improve patient outcomes.
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Introduction
The realization that angiogenesis is essential for tumor
growth, invasion and metastasis led to the development of anti-
angiogenic therapies [1]. A number have been tested, however,
toxicity issues thwarted potentially promising outcomes [2].
Strategies that target vascular endothelial growth factor
(VEGF) can be transiently successful until sabotaged by tumor
up-regulation of other pro-angiogenic factors [3]. Copper (Cu),
a trace metal involved in many essential processes, such as
energy metabolism and hemoglobin production, also plays an
integral role in tumor angiogenesis by functioning as a critical
co-factor for several pro-angiogenic molecules including VEGF,
basic fibroblast growth factor (bFGF), and angiogenin [4,5].
Therefore, therapeutic copper reduction achieved by lowering
the levels of bioavailable copper using copper chelators,
represents an anti-cancer approach that targets multiple pro-
angiogenic factors and is reported to be relatively non-toxic
[6,12].
Importantly, decreasing bioavailable copper has shown
promising results in animal models and in clinical trials in
different cancers [6–10], including a single post surgical trial in
patients with malignant mesothelioma [11]. Copper lowering
may modulate tumor blood vessels to normalize them, i.e.
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render them more phenotypically, structurally and functionally
similar to vessels in normal healthy tissue, as demonstrated in
a brain cancer rabbit model [12]. In that model, lowering the
concentration of local copper reduced the abnormally high
proliferative rate of tumor endothelia to the more quiescent rate
seen in normal brain tissue [12]. Furthermore, tumor vessel
width was reduced to a similar width seen in the healthy brain
vessels. Beneficial consequences of vessel normalization may
be facilitation of immune cell infiltration and/or enhanced
immune cell function [13–15]. We address these issues using a
murine mesothelioma model.
Malignant mesothelioma is characterized by an abnormal
proliferation of serosal-surface mesothelial cells and is
associated with asbestos exposure [16]. Mesothelioma patients
have a mean survival of 12 months after diagnosis and the
incidence is rising worldwide due to past, recent and in some
cases current exposure to asbestos. The poor prognosis of this
cancer on account of resistance to conventional treatment
strategies including surgery, chemotherapy and radiation,
warrants the search for alternative treatment options. The
present study determines (i) if and when developing
mesothelioma tumors take up copper, and (ii) if copper-




Female C57BL/6J mice aged 6 to 8 weeks obtained from the
Animal Resource Centre (Perth, Western Australia (WA) were
maintained under Specific Pathogen Free conditions in the
Curtin University animal holding facility. All mouse experiments
were performed according to the Australian Code of Practice
for the care and use of animals for scientific purposes as per
Curtin University Animal Ethics Committee (AEC) approval
numbers AEC-2011-01 and AEC-2011-16. Mice were provided
a standard meat free rat and mouse diet (Specialty Feed,
Perth, Western Australia) ad libitum which, according to the
manufacturer, contains 0.0016% copper or 16 µg copper per
gram chow.
Cell lines and in vivo tumor growth
AE17 is a mesothelioma cell line derived in C57BL/6J mice
after intraperitoneal (i.p.) inoculation of asbestos fibres [17].
AE17 cells were maintained at 37 °C in 5% CO2 in RPMI 1640
media (Invitrogen, CA, USA) supplemented with 10% fetal calf
serum (FCS) (Invitrogen, CA, USA), 50 µg/ml gentamicin
(Sigma Aldrich, USA) and 100 U/ml penicillin (Sigma Aldrich).
At 80% confluency, cells were trypsinized, washed with PBS
(Invitrogen) and cell numbers determined using trypan blue
(Sigma Aldrich). Subcutaneous (s.c.) inoculation of 5 × 105
AE17 cells in 100 µl of PBS into mice produces tumors
histologically similar to human mesothelioma [17]. Tumor sizes
were determined by multiplying two perpendicular axes that are
at right angles to each other (measured using microcallipers) to
get an area calculation. Note that tumor volumes were not
determined as the tumors do not reliably develop into spherical,
ellipsoid, or hemi-ellipsoid shapes that have defined formulae
to use. Human umbilical vein endothelial cells (HUVECs,
ATCC-CRL-1730; American Type Culture Collection, VA, US)
were maintained in endothelial cell medium (ECM)
supplemented with endothelial cell growth supplement, foetal
bovine serum penicillin and streptomycin (all from ScienCell
Research Laboratories) at 37°C in 5% CO2.
Using the MTT assay to measure cell viability and
proliferation
The 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay is based on the cleavage of the yellow
tetrazolium salt (MTT) to purple formazan crystal by
metabolically active cells and is used to measure the level of
energy metabolism occurring in cells, as well as cell viability
and cell proliferation. Previously identified optimal
concentrations (5 x 103) cells/well were seeded in flat bottom
96-well plates (Becton Dickinson (BD) USA) and incubated in
200 µl/well for 24 hrs when 50 µl of 2mg/ml MTT (Sigma
Aldrich) in PBS was added. Cells were incubated at 37°C for 4
hrs, centrifuged at 1,000 rpm at 4°C for 5 mins, supernatant
removed and 100 µl of dimethyl sulfoxide (DMSO; Sigma
Aldrich) added to each well. Plates were incubated in the dark
for 30 mins at room temperature (RT) with shaking and
absorbance determined using a Biorad 3550 microplate reader
at 595 nm.
Cell cycle analysis
Staining DNA in intact ethanol-fixed cells with propidium
iodide (PI) can be used to determine which phase of the cell
cycle (G0, G1, S, G2 or M phase) a cell is in after exposure to
a specific treatment. PI, a fluorescent dye, passes through the
ethanol-permeabilized cell membrane and is incorporated into
the DNA. The intensity of the PI signal is directly proportional to
DNA content which identifies the cell cycle phase. AE17 cells
were seeded at 5 x 105 cells/well using 6-well plates (BD),
incubated for 24 hrs, given the relevant treatment, and
incubated for a further 24 hrs. Cells were trypsinized,
harvested, centrifuged at 1,350 rpm for 10 mins then re-
suspended in glucose buffer (1g glucose/L PBS) and washed
twice in glucose buffer prior to overnight (O/N) fixing in 70%
ethanol at 4°C. Fixed cells re-suspended in 1 ml of a 50 mg/ml
(PI; Sigma Aldrich) solution in glucose buffer containing 2
mg/ml ribonuclease A (Sigma Aldrich) were incubated in the
dark at RT for 30 mins prior to flow cytometric analysis.
In vivo copper depletion and targeting VEGF in vivo
Mice offered copper-free milli-Q water (Ibis Ultra Pure water
system) and mouse chow (Able Scientific, WA) ad libitum were
given penicillamine, trientine or tetrathiomolybdate(TM) (Sigma
Aldrich). Penicillamine and trientine deplete copper by binding
free copper in blood and tissues, creating a stable soluble
complex that is excreted in urine [18]. Penicillamine is a
reductive copper chelator that lowers the affinity of copper for
protein and allows it to be chelated [19]. Trientine increases the
excretion of copper and decreases intestinal copper absorption
[20]. TM forms a stable tripartite complex with copper and
serum albumin, rendering it unavailable for cellular uptake, this
complex is slowly cleared in bile and urine [4]. Low,
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intermediate and high doses based on previous studies
[5,6,18,21,22] were administered via i.p. injection in 200 µl of
copper-free Milli-Q water. Mice were monitored for behavioral
or physical changes that indicate toxicity. In one series of
experiments, VEGF was targeted using the anti-VEGF-
receptor(r) monoclonal antibody, DC101 [23], purchased from
the Western Australian Medical Institute for Medical Research
(WAIMR) Monoclonal Antibody Facility (Perth, Western
Australia). Mice were given 3 i.p. doses (800 µg in 800 µl) of
the anti-VEGFr antibody every 3 days as previously described
[23].
Harvesting tissues for copper analysis
After collecting blood via cardiac puncture using a
heparinized (David Bull Laboratories, UK) 1 ml syringe (BD,
CA, USA) mice were perfused with 15 mls of cold PBS
containing 10 units/ml of heparin until the organs blanched.
Organs and tumors were collected, washed twice in Milli-Q
water, wet weights recorded and frozen. Upon thawing,
samples were homogenized using a Heidolph DIAX 900 into 8
volumes of water (e.g. 100 µg in 800 µl). A 300 µl aliquot was
lyophilised (Edwards EF4 Modulyo Freeze dryer) for 5 hrs, dry
weights recorded and then digested in a 2:1.6 (vol: vol) mixture
of 70% Nitric Acid (Sigma Aldrich) and 30% hydrogen peroxide
(Sigma Aldrich) and heated to 100°C for one hour as described
[24]. Digested samples were diluted to 4 mls with Milli-Q water
and blood samples were diluted 1:200 in 1% Triton–X-100.
Determining copper levels
Atomic absorption spectrophotometric (AAS) analysis was
used to determine the concentration of copper in digested
tissue and blood samples. A hollow copper cathode lamp
operating at 4 mA was used, and the spectrophotometer set to
read absorbance at 327.4 nm with a spectral bandwidth of
0.5nm. Standard curves ranging from 0 µg/L to 120 µg/L were
created using a copper nitrate, Cu(NO3)2 standard (Varian,
Australia). Using the spectraAA 640Z (Varian, Australia) with a
GTA-100 autosampler, 20 µl of each processed sample was
injected into a graphite tube (Varian, Australia), which was
heated according to the protocol outlined in Table 1. Each
sample was measured in triplicate, the mean absorbance was
compared to the standard curve and the copper concentration
calculated after background correction was performed using an
inbuilt Zeeman apparatus. A second machine was also used,
GBC Avanta 908G, with the same parameters as described
above.
AE17 cells were digested in 300 µl of 70% HNO3 (Riedel-de
Haën, Germany) at 90°C for 30 mins and 200 µl of 40% H2O2
(Sigma Aldrich) for 10 mins at 70°C until the solution became
clear. Milli-Q water was added to give a final volume of 5 mls
and copper levels measured using inductively coupled plasma-
mass spectrometry (ICP-MS; TSW Analytical Pty Ltd,
Biomedical, University of WA, Perth, Australia).
Determining plasma ceruloplasmin levels
The majority of serum copper is transported bound to
ceruloplasmin thus it can be used as a surrogate maker for
blood copper levels [25–27]. A 25 µl sample of plasma was
added to 375 µl of 0.1 mol/L sodium acetate (pH 5), incubated
at 30 °C for 5 mins and 100 µl of substrate (O-dianisidine
dihydrochloride) (Sigma Aldrich) added. One of a duplicate
sample was incubated at 30 °C for 25 mins (described as A25 in
the formula below) whilst the remaining duplicate was
incubated for 40 mins (A40). This assay determined the
enzymatic activity of the ceruloplasmin between the two time
points by its oxidation of the substrate to a yellow product. One
ml of 9 mol/L sulfuric acid (H2SO4) was added to quench the
reaction and form a stable pink product, which was analyzed at
540nm. Ceruloplasmin activity was determined using the
following equation:
Ceruloplasmin Activity IU/ml = (A40-A25) × 6.25×10-1 (Where
0.625 is a factor that takes into account dilution factor of 60,
incubation of 10, light path of 1 cm, and an absorptivity of 9.6
µmol/ml).
Harvesting tumors and lymphoid organs
Spleens, draining (dLN) and non-draining lymph nodes
(ndLN) were disaggregated into single cell suspensions by
gently mashing between two frosted slides, removing debris,
centrifugation at 1200 rpm for 5 mins and re-suspension in 2%
FCS in PBS.
Assessing immune cells and blood vessels using flow
cytometric analysis
Cell samples were incubated in the dark for 30 mins at 4°C
with 50 µl buffer containing the antibodies (Ab) described
below, washed twice in PBS/2% FCS and re-suspended in 2%
paraformaldehyde for flow cytometry analysis. Markers for
mouse endothelial cells were anti-CD31 (PECAM; Biolegend,
San Diego, CA, USA); Alexa Fluor® 647-conjugated-anti-CD34
(found on normal endothelial cells and stem cells [28]), PE-anti-
CD105 (Endoglin, a regulatory component of TGF-β receptor
specific for tumor angiogenesis [28]), Alexa Fluor® 647-anti-
CD106 (vascular cell adhesion molecule; VCAM) expressed on
activated endothelial cells; all from eBioscience, San Diego,
CA, USA. FITC-anti-CD54 (intracellular adhesion molecule-1,
ICAM-1; BD Pharmingen, CA, USA) is expressed on activated
endothelial cells. Ki67 is an intracellular marker of proliferation.
Table 1. Furnace Parameters used in Atomic Absorption
Spectrophotometry.
Temp (°C) Time (seconds)* Gas Flow (L/min) Gas type Read absorbance
80 6 3.0 Nitrogen No
90 40 3.0 Nitrogen No
110 11 3.0 Nitrogen No
800 5 3.0 Nitrogen No
800 1 3.0 Argon No
800 2 0 Argon No
2300 1.1 0 Argon Yes
2300 2 0 Argon Yes
2300 2 3.0 Nitrogen No
*. Values refer to ramping time, the time taken to increase temperature within the
graphite tube from previous temperature to the current temperature.
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Surface staining was first performed as described above. Cell
membranes were then fixed and permeabilised using fixation/
permealisation buffer (Biolegend), washed and further
incubated with permealisation buffer (Biolegend) as per
manufacturer’s instructions. The cells were then incubated with
FITC-anti-Ki67 (BD Pharmingen) for 30 mins in the dark. For
immune cell analysis single cell suspensions were co-stained
with APC Cy7-anti-CD3 and PE-anti-CD8 (both from BD
Pharmingen), as well as PECy5.5-anti-CD4 and/or PE-anti-
CD19 (both from Biolegend), and FACS analyzed. All flow
cytometry data was acquired on a FACS Canto II using FACS
Diva Software. FlowJo software was used to analyze the data.
Assessing blood vessels using immunofluorescence
Frozen sections (10 µm) of OCT-embedded tumors were
fixed in cold acetone for 10 mins, air dried, and treated with
PBS/5% FCS for 30 mins at RT. FITC-anti-CD31 (PECAM;
Biolegend) or isotype control (rat IgG2a; BD, Mountain View,
CA) were applied for 45 mins at RT. Sections were rinsed in
PBS/5% FCS and mounted using VectaShield (Vector
Laboratories, Burlingame, CA, USA). Slides were visualized on
an UltraVIEW VoX confocal imaging system with Volocity 6.0.1
software (PerkinElmer, Massachusetts, USA). Blood vessel
measurements were calculated using Volocity 6.0.1 software.
Statistical analysis
The student t-test and one-way analysis of variance
(ANOVA) were used to determine differences between two or
more populations respectively using GraphPad PRISM 4.0.
Differences were considered significant if p < 0.05.
Results
Tap water is a source of consumed copper
Copper levels in drinking water were measured to address
the significance of water contributing to overall dietary copper
absorption. Tap water contained high copper levels (Figure
S1A) that were significantly reduced by filtration and ultra
purification (Milli-Q) methods. Mice maintained on tap water
appeared to contain higher levels of copper in livers and
kidneys than mice maintained on Milli-Q water (Figure S1B)
however, the differences did not reach statistical significance.
These data suggest that food is a significant source of copper.
Nonetheless, mice in all of the following experiments were
maintained on Milli-Q filtered water and the copper chelating
reagents were diluted in Milli-Q water to reduce copper
consumption.
Mesothelioma tumors rapidly sequester copper in vivo
Copper levels in tumors and tissues were measured during
mesothelioma tumor growth (Figure 1A). Copper analysis on a
per gram basis in terms of tumor size (Figure 1B), or tumor
weight (Figure 1C), shows that mesothelioma tumors had their
greatest concentrations at early stages of tumor evolution with
concentrations over 5 times that found in livers and kidneys
(Figure S2). Total copper levels (Figure 1D) and copper levels
per gram (Figure 1B and C) then dropped considerably,
suggesting that accumulated copper was dispersing throughout
growing tumor tissues faster than their ability to mobilize
copper into the tumors.
Mesothelioma tumors do not induce changes to copper
levels in other organs
No significant changes in copper concentrations in livers,
kidneys, lungs and spleens (Figure S2A, S2B, S2C and S2D
respectively) were seen in mesothelioma-bearing mice during
disease progression. The levels in these organs are similar to
those previously reported by others [24,26], thus these tissues
also functioned as a useful internal control.
Bioavailable copper levels are reduced in vivo using
copper lowering agents
We then aimed to identify an in vivo treatment protocol that
would reduce bioavailable copper levels. Penicillamine [29–31],
trientine [32–34] and TM [9,35,36] have been described as
effective copper lowering agents, hence we analyzed their
effectiveness in 6 week old mice weighing between 21 and 23
grams. The high TM dose (1000 µg per mouse) and both
penicillamine doses (2000 µg and 10,000 µg per mouse) led to
a decrease in plasma ceruloplasmin levels 5 days after
treatment relative to Day 0 ceruloplasmin levels taken before
treatment commenced (Figure 2A and C). Both doses of
trientine (700 µg and 1000 µg per mouse) appeared to
transiently increase ceruloplasmin levels at day 2 yet they
returned to baseline levels by day 5 (Figure 2E). All doses of
trientine and penicillamine treatment caused a decrease in liver
copper levels (Figure 2D and F). As ceruloplasmin is used as
surrogate marker for blood copper levels the results suggest
that both penicillamine and trientine mobilize copper into blood
before eliminating it, and liver copper levels decreased rapidly
with trientine treatment and more slowly with penicillamine
treatment. In contrast, liver copper levels in TM treated-mice
transiently increased before decreasing to below day 0 levels
(Figure 2B) suggesting the mobilization and accumulation of
copper in the liver before its excretion. Whilst no macroscopic
signs of toxicity were observed at any dose used, the doses
chosen for subsequent experiments were: TM 500 µg per dose
per mouse; trientine 700 µg per dose per mouse; penicillamine
2000 µg per dose per mouse.
Therapeutically lowering bioavailable copper slows
mesothelioma tumor growth rate
We next aimed to determine if lowering bioavailable copper
could be used therapeutically by commencing treatment after
mesothelioma tumors have been established in vivo. To do
this, the three copper depleting strategies were commenced
when established tumors reached 20-25 mm2. All three agents
slowed mesothelioma growth (Figure 3A) and tumors in
trientine and TM-treated mice were significantly smaller than
the controls. In a separate experiment, the in vivo anti-tumor
activity of TM was compared to cisplatin, a cytotoxic agent
often included in the treatment regimen for mesothelioma
patients. Again, treatment with TM or cisplatin commenced
when tumors reached 20-25 mm2. TM and cisplatin were
equally efficacious to each other and each significantly slowed
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Figure 1.  Developing mesothelioma tumors rapidly acquire copper.  Mice were sacrificed when tumors reached 1-16 mm2,
20-50 mm2 and > 50 mm2. Tumor growth rate shown in A. Copper levels from the different sized tumors (B); pooled data from 4
experiments, with n = 19 mice with 1-16mm2 tumors; n = 10 mice with 20-50mm2 tumors; n = 16 mice with > 50mm2 tumors; and n =
10 control mice is shown as mean ± SEM. Copper levels are also shown as individual weighed tumor samples to better reflect tumor
size (C). Cu levels in whole tumor tissue relative to individual tumor weights are also shown (D).
doi: 10.1371/journal.pone.0073684.g001
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Figure 2.  Bioavailable copper levels can be decreased in vivo by copper chelating agents.  Low, medium and high doses of
TM (A and B), penicillamine (C and D) and trientine (E and F) were administered i.p. to healthy mice over 5 days. Mice were
sacrificed on days 0, 2 and 5 Plasma ceruloplasmin (Cp) was assayed (A, C and E), and liver Cu levels analyzed (B, D and F). For
Cu levels n = 3 mice/group. For Cp assays there were 11 mice for TM at day 0, these mice were divided into groups and given
different doses of TM; 1 mouse/TM dose was culled and sampled at day 2 (n = 1/group) for each of the three doses; 3 mice were
sampled for each of the 200 µg and 1000µg TM doses (n = 3/group), and 2 mice sampled for the 500µg TM treatment at day 5 (n =
2/group). For penicillamine and trientine there were 4 mice per treatment dose at day 0 (n = 4) and 1 mouse sampled at each time
point for each dose (n = 1/group). Where possible, data is shown as mean ± SEM.
doi: 10.1371/journal.pone.0073684.g002
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tumor growth (Figure 3B). Finally, in another experiment the in
vivo anti-tumor activity of an anti-angiogenic strategy that
prevents VEGF action by blocking the VEGR receptor (VEGFr)
was examined using the rat anti-murine VEGFr monoclonal
antibody (DC101). The anti-VEGFr antibody treatment,
commenced when tumors reached 20-25 mm2, also slowed
tumor growth (Figure 3C). These data show that anti-
angiogenic approaches such as copper depletion and anti-
VEGFr beneficially interfere with mesothelioma tumor growth.
Prophylactically lowering bioavailable copper
transiently slows mesothelioma tumor growth rate
We also aimed to determine if lowering bioavailable copper
could be used prophylactically by commencing the three
copper depleting strategies two weeks before mesothelioma
tumors were implanted and then maintaining treatment to the
end of the experiment. The copper-depleting treatments, in
particular trientine, appeared to delay tumor growth for 35 days
post tumor cell inoculation. After day 35 tumor growth in all
copper depleting treatment groups had caught up with, or
overtaken, the controls (Figure S4A).
Saturating the tumor microenvironment with high
copper levels does not accelerate tumor growth
We conducted two different approaches to see if high copper
levels would promote tumor growth. Firstly, we pre-loaded
copper by giving mice copper acetate in their drinking water at
500 mg/L two weeks prior to inoculation with AE17 tumor cells.
Secondly, we post-loaded copper by allowing tumors to
develop to 1-4 mm2 sized tumors before copper acetate was
included in the drinking water. Tumor growth was barely
perturbed in the pre-copper loading experiment and,
unexpectedly, was slowed in the post-copper loading
experiment.
Copper lowering is not directly toxic to mesothelioma
tumor cells or endothelial cells
MTT assays were used to determine if copper depletion
affects AE17 tumor cell growth, metabolic activity and/or
viability, which could account for the slowed tumor growth rates
shown in Figure 3A. The results showed that TM, penicillamine
and trientine did not exert a significant effect on tumor cell
proliferation at the log fold concentration range examined
(Figure S3A, S3B and S3C). These data suggest that copper
lowering is not directly toxic to mesothelioma tumor cells, thus
other mechanisms must be contributing to the slowed tumor
growth. It has been suggested that copper lowering targets
tumor blood vessels [6,37–39]. Therefore, HUVECs were used
to determine the effect of copper lowering on normal healthy
endothelial cells. HUVECs continued to proliferate in the
presence of TM and trientine (Figure 4A and C) at similar levels
to the controls. Treatment with penicillamine slightly increased
their proliferation relative to the controls (Figure 4B).
Figure 3.  Reducing bioavailable copper slows tumor
growth rate.  AE17-bearing mice were given daily PBS, TM
(500 µg/dose/mouse), penicillamine (2000 µg/dose/mouse) and
trientine (700 µg/dose/mouse) throughout tumor growth (A).
Pooled data is from one experiment (n = 4 or 5 mice/group). In
a separate experiment, AE17-bearing mice were given
cisplatin, TM or PBS; n = 6 mice/group (B). In another
experiment AE17-bearing mice were given i.p. injections (800
µl) of PBS or 800 µg/dose/mouse anti-VEGFr antibody (C) (n =
10 mice/group). Arrow indicates when treatment was
commenced. All data are shown as mean ± SEM. * p < 0.05.
doi: 10.1371/journal.pone.0073684.g003
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Figure 4.  Decreasing bioavailable copper in vivo modulates tumor vessel dimensions.  HUVECs (5 x 103) were treated in
vitro with PBS (control is shown as the black line) or log fold concentrations of tetrathiomolybdate (A), penicillamine (B) and trientine
(C) and MTT assays performed 24 hrs later. Data from n = 2 experiments each with its own triplicates is shown as mean ± range.
Mice treated with PBS, TM, penicillamine or trientine were sacrificed when tumors reached 100 mm2 and tumor-associated vessels
visualized and measured on frozen tumor sections using FITC-anti-CD31 antibody and confocal imaging. Representative
photographs are from individual mice that were not treated (control: D), given TM (E) or penicillamine (F). Pooled data counting a
minimum of 100 cells per mouse showing tumor blood vessel (BV) diameter (G) and length (H) from control (normal mice; n = 4),
penicillamine (Pen; n = 2), trientine (TT; n = 2) or Tm-treated (n = 2) mice are shown as mean ± SEM. * p < 0.05, ** p < 0.005.
doi: 10.1371/journal.pone.0073684.g004
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Copper lowering in vivo modulates tumor endothelial
cells
The data above suggests that the copper chelating reagents
are not toxic to endothelial cells and the penicillamine results
implied the potential for endothelial cell activation. Therefore,
the next series of experiments assessed the effect of copper
lowering on mesothelioma-associated tumor blood vessels in
vivo. Blood vessels connecting draining inguinal lymph nodes
and tumors appeared to shrink in diameter in TM and trientine
(TT) treated mice (not shown), similarly, the diameter of tumor-
associated vessels decreased (Figure 4D, E and G), while
vessel length increased (Figure 4D, E and H) in the same mice.
Penicillamine appeared to increase tumor vessel diameter but
not length (Figure 4F, G and H). These data suggest that blood
vessel structure is being affected by copper lowering
strategies.
We then hypothesized that copper lowering may normalize
tumor vessels as previously described [14]. This could be
identified by increasing numbers of normal endothelial cells,
likely recruited from circulating precursors, and reduced
endothelial cell activation, the latter driven by tumor cell-
derived factors. Thus, to further examine the effect of copper
lowering on tumor vessels excised tumors were disaggregated
into single cell suspensions and flow cytometry used to identify
angiogenic and normal endothelia [28]. Unexpectedly, all
agents led to a significant increase in the proportion of total
gated CD31+ endothelial cells that represented CD31+CD105+
angiogenic endothelial cells (Figure 5A to D) however, the
overall percentages were low. TT and TM induced a significant
increase in the proportions of normal CD31+CD34+ endothelial
cells (Figure 5E) with a reduced activation status revealed by
lower proliferation (Ki67) and lower surface ICAM/CD54
expression (Figure 5F). In contrast, normal endothelial cells
continued to proliferate when exposed to penicillamine in
agreement with the data shown in Figure 4B. A small number
of CD31+CD34+ endothelial cells co-expressed CD105 which
may indicate transition into angiogenic endothelia; the
proportions of these triple positive cells were also reduced in
response to copper depletion strategies (Figure 5F). The most
effective agents in promoting normal CD31+CD34+ endothelial
cells were TM and TT. These data imply that reducing
bioavailable copper normalizes tumor vessels.
Copper lowering promotes CD4+ T cell infiltration into
the tumor microenvironment
Others have shown that normalized tumor vessels become
permissive to immune cell infiltration [15]. Thus, we used flow
cytometry to measure changes to tumor-infiltrating CD4+ and
CD8+ T cells. A significant increase in CD4+ T cells was seen in
AE17 tumors treated with penicillamine and trientine (Figure 6A
to D). An apparent but not statistically significant increase in
CD4+ cells was also observed in TM treatment. No change was
observed in CD8+ T cell levels.
Discussion
To our knowledge, no previous studies have examined the
role of copper in mesothelioma tumors. This study found that
murine mesothelioma tumors rapidly accumulate copper as
they progress. The biggest change was seen in small early
stage tumors. It is interesting to note that copper
concentrations in organs, such as the liver, show a similar
pattern of high concentrations during fetal growth; these levels
then decline due to their gradual use and dispersal throughout
the growing tissue [24,40]. Copper’s role in angiogenesis, and
therefore in organ development, may explain the rapid copper
acquisition seen in fetal tissues. Thus, copper may play an
important role in the early stages of mesothelioma tumor
development by supporting angiogenesis, as described in other
tumors [41].
Reduction of bioavailable copper was tested using copper
lowering agents combined with copper-depleted drinking water.
We used copper-depleted water because it was relatively easy
to remove copper from water and it ensured that changes in
drinking rates would not affect our results. However, the food
contained copper and the average mouse consumes about 4.5
g of food per day [42] which equates to 72µg copper.
Nonetheless, despite copper replenishment by food
penicillamine and trientine reduced liver copper levels at all
doses examined. In contrast, TM showed a transient increase
in liver copper levels before a rapid decrease, which may
reflect copper being mobilized from other organs to the liver
before excretion via the bile. Copper bound to ceruloplasmin
increases angiogenic activity and correlates with tumor
progression [43]. Thus, in clinical trials the first goal of anti-
cancer copper reduction is to reduce ceruloplasmin levels to
20% of the patient’s normal baseline [27]. Penicillamine and
TM were more effective at lowering ceruloplasmin levels in the
blood than trientine. Optimal doses were chosen based on the
lowest dose that lowered liver copper and ceruloplasmin whilst
maintaining a threshold level of copper required for essential
body functions. The latter was indicated by monitoring the
general health status of mice. Note that future studies will use a
copper depleted diet to further evaluate our work.
Limiting bioavailable copper has been shown to slow tumor
growth in other cancers [4–12]. In this study copper lowering
with TM and trientine significantly slowed murine AE17
mesothelioma tumor growth rate. Nonetheless, TM and
trientine treatment did not offer long-term survival with all mice
eventually succumbing to tumors. These data were similar to
the standard platinum chemotherapy, cisplatin, as well as to an
anti-angiogeneic strategy that blocks the function of VEGF, i.e.
both as monotherapies induced transient tumor regression
before tumor progression. It is possible that combining
decreasing bioavailable copper with chemotherapy and/or
other vascular targeting strategies may provide an improved
outcome. It should be noted that the anti-angiogenic effect of
copper deficiency, induced by TM at least, is via suppression of
NF kB including NF kB-mediated transcription of pro-angiogenic
factors [5]. Therefore, some chemotherapeutic agents, such as
doxorubicin, but not all, can be combined with copper
depletion. Indeed, we now have preliminary data showing that
combining copper depletion treatment with cisplatin is
antagonistic (data not shown). The only clinical trial in
mesothelioma patients reported to-date was a combination
therapy in which TM therapy was given post surgery, and the
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Figure 5.  Copper lowering in vivo reduces tumor endothelia proliferation and ICAM (CD54) expression.  Mice treated with
PBS, TM, penicillamine or trientine were sacrificed when tumors reached 100 mm2 and tumor endothelia analyzed by flow
cytometry. Single cells were identified by excluding doublets by gating on FSC-A versus FSC-H plots; A. Isotype controls and single
stains were used to set up negative and positive regions (not shown). Lymphocytes were excluded by gating. Backgating on
CD31+CD105+ revealed the FSC/SSC region associated with tumor blood vessels (BV:B). CD31+CD105+ angiogenic (C and D) or
CD31+CD34+ normal (E) endothelial cells were identified, gated and quantified. The proportions of Ki67+, CD105+ and CD54+ cells
within each gate were determined (F). Pooled data counting > 20,000 CD31+CD105+ or CD31+CD34+ cells per mouse from 2 mice/
treatment group and 4 control mice is shown as mean ± SEM. * p < 0.05; *** p < 0.001.
doi: 10.1371/journal.pone.0073684.g005
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data showed that the time to disease progression was slowed
by 10 months [11]. As the current survival time for patients with
mesothelioma is 12 months post diagnosis any therapy that
increases survival time could make a considerable difference in
the lives of these patients. Further studies are required to
address combination with other treatment modalities.
Our studies showed that commencing copper depletion two
weeks prior to tumor cell inoculation transiently delayed
mesothelioma tumor growth for 31 to 35 days depending on the
treatment used. Similarly, depleting copper after mesothelioma
tumors were established but at a time when the tumors
appeared to be dispersing rather than rapidly acquiring copper
led to delayed tumor growth. Previous work has shown that
tumors cannot grow past the angiogenic switch in a copper
depleted environment [5]. However, some trials have shown
that copper depletion has little affect on tumor growth [44,45],
and it is possible that once tumors are fully angiogenic
depleting copper will have little effect. One possible
interpretation of our data is that the mesothelioma tumors did
not reach true angiogenesis and until around day 31 and
therefore remained susceptible to copper depletion until that
time. These data contrast to our data generated in concurrent
and identical experiments we conducted using the Lewis Lung
carcinoma cell line. In this lung cancer model, copper depletion
prior to tumor cell inoculation was more effective in delaying
tumor growth (data not shown) than in the mesothelioma
model. Yet and in contrast to the mesothelioma model, copper
depletion after LL tumors were established was not effective
(data not shown), implying a rapid angiogenic switch in the LL
model. We did not measure copper accumulation in
mesothelioma or LL tumors developing in an environment
initially depleted of copper, nor did we release tumors from
copper depletion. This will be the subject of future studies.
We also attempted to copper load mice to accelerate in vivo
tumor growth in both models. Pre-loading with copper had little
impact on mesothelioma tumor growth whilst copper loading
post tumor cell inoculation appeared to be toxic to the
mesothelioma microenvironment as copper-loaded tumors
Figure 6.  Copper lowering in vivo promotes CD4+ T cell infiltration.  Mice treated with PBS, TM, penicillamine or trientine were
sacrificed when tumors reached 100 mm2 and immune cell infiltration analyzed by flow cytometry. The SSC/FSC-A plot revealed the
lymphocyte population (A). CD3+ regions were determined using the CD3-APC-Cy7 single stain (B). Triple staining identified
CD3+CD4+ or CD3+CD8+ cells; representative contour plot (C). Pooled data from 2 mice/group shown as mean ± SEM (D). * p <
0.05.
doi: 10.1371/journal.pone.0073684.g006
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grew at a slower rate. Again, this contrasted to the LL model in
which copper loading promoted tumor growth (data not shown).
The data are difficult to interpret, however one possibility is that
copper levels were already at the highest possible
physiological concentrations required for mesothelioma, but not
LL, angiogenesis and that increased copper levels become
toxic to mesothelioma development. These data suggest that
different models may have different copper requirements, as
the mouse models are both in C57BL/6 mice and were s.c.
implanted using the same number of tumor cells.
Copper depletion induced structural and functional changes
in tumor-associated blood vessels. Changes to the length and
diameter of tumor blood vessels coincided with a significant
increase in the proportion of endothelial cells that were less
activated, i.e. reduced ICAM (CD54) and lower proliferative
levels. These data suggest that vessel normalization had been
induced. It is possible that these normalized cells represent
newly recruited (CD31+CD34+) endothelial cells that were
progressing toward an angiogenic phenotype; the acquisition of
CD105+ supports this hypothesis. These data are in agreement
with an early study using a rabbit brain tumor model in which
copper lowering reduced tumor vessel width, as well as the
proliferative rate of tumor endothelia, to similar levels seen in
healthy brain vessels [12]. Similarly, a recent study has shown
that copper plays an important role in vascular inflammation,
and that copper chelation with TM may have value as an anti-
inflammatory or anti-atherogenic agent [26]. In those studies
mice treated with TM demonstrated significant inhibition of
lipopolysaccharide-induced inflammatory gene transcription
and protein levels of VCAM-1, ICAM-1 and monocyte
chemotactic protein-1 in the aorta and heart. Thus, reducing
bioavailable copper may return activated/inflamed angiogenic
endothelial cells to a more normal state [13].
A significantly higher CD4+, but not CD8+, T cell infiltrate was
seen in mesothelioma tumors undergoing copper lowering
therapy. These data imply that reducing copper levels renders
blood vessels to become permissive to CD4+ T cell infiltration.
The reasons for this selective recruitment are unclear. One
possibility is changes to expression of specific adhesion
molecules. An interesting molecule that may control CD40L
+CD4+ T cell adhesion to endothelium is CD40 which can be
expressed at higher levels by tumor endothelial cells relative to
endothelia in normal tissues [46,47]. The effect of copper
lowering on CD40 expression by tumor vessels is as yet
unknown and further studies are required. It is also possible
that the CD4+ T cells recruited into tumors represent a T cell
subset such as the CD4+CD7- subset which can preferentially
adhere to endothelial cells via ICAM and E-selectin (CD62E),
the ligand of which, cutaneous lymphocyte-related antigen
(CLA), is highly expressed in CD4+CD7- T cells [48]. Further
studies are required to elucidate the molecular mechanisms
underlying CD4+ T cell selection and CD4+ T cell function in the
tumor microenvironment.
Here we show that copper is rapidly sequestered into
developing mesothelioma tumors and that therapeutic copper
removal from organs, the circulation and the tumor itself slows
tumor growth. Our findings suggest copper lowering modulates
tumor blood vessels such that they are transiently ‘normalized’
to promote immune cell infiltration into the tumor
microenvironment. These data suggest combination with
immunotherapy should be investigated. We propose that
copper lowering is a potentially useful and relatively non-toxic
anti-mesothelioma strategy that slows tumor growth to provide
a window of opportunity for inclusion of other treatment
modalities to improve outcomes for mesothelioma patients.
Supporting Information
Figure S1.  Tap water is a significant source of copper.
Tap water from the animal facility was analyzed for Cu, before
and after aqua pure (filtered) or Milli-Q filtration (A); one
sample, data shown as mean of each triplicate. Mice from the
same facility were given either tap or Milli-Q water ad libitum for
10 days, before their organs were analyzed for Cu levels;
pooled data from 6 mice/group is shown as mean ± SEM (B).
(TIF)
Figure S2.  Mesothelioma tumors do not affect copper
levels in other organs.
AE17 tumor-bearing mice were sacrificed at varying timepoints
and liver (A), kidney (B), lung (C) and spleen (D) Cu levels
measured. Pooled data from the same four experiments
described for Figure 2 is shown as mean ± SEM.
(TIF)
Figure S3.  Copper lowering is not toxic to mesothelioma
cells in vitro.
AE17 tumor cells (5 x 103) were treated in vitro with log fold
concentrations of tetrathiomolybdate (A), penicillamine (B) and
trientine (C) and MTT assays performed 24 hrs later. Data was
normalised to control cells (black line). Pooled data from 3
experiments each with its own triplicates is shown as mean ±
SEM.
(TIF)
Figure S4.  Copper lowering prior to tumor cell inoculation
slows tumor growth.
Mice received daily i.p. injections of penicillamine (2000µg),
trientine (700µg) or TM (200µg) for 2 weeks (starting day -14;
pre Cu depletion: A) prior to AE17 tumor cell inoculation (on
day 0), copper lowering continued until the mice were culled (n
= 6 mice per experimental group). Copper loading was
achieved by giving mice copper acetate in their drinking water
at 500 mg/L two weeks prior to inoculation with AE17 tumor
cells (n = 6 mice/group; pre-loading: B), or by allowing tumors
to develop to 1-4 mm2 sized tumors before copper acetate was
continuously included in the drinking water (n = 5 mice/group;
post-loading: C). Data shown as mean ± SEM.
(TIF)
Acknowledgements
The authors acknowledge the CHIRI Biosciences Research
Precinct core facility.
Lowering Cu Slows Tumors and Normalizes Vessels
PLOS ONE | www.plosone.org 12 August 2013 | Volume 8 | Issue 8 | e73684
Author Contributions
Conceived and designed the experiments: AC DJN. Performed
the experiments: AC CJ KMB BR DJN. Analyzed the data: AC
CJ KMB BR DJN. Contributed reagents/materials/analysis
tools: AC DJN. Wrote the manuscript: AC KMB BR DJN.
References
1. Folkman J (2007) Angiogenesis: an organizing principle for drug
discovery? Nat Rev Drug Discov 6: 273-286. doi:10.1038/nrd2115.
PubMed: 17396134.
2. Sun S, Schiller JH (2007) Angiogenesis inhibitors in the treatment of
lung cancer. Crit Rev Oncol/Hematol 62: 93-104. doi:10.1016/
j.critrevonc.2007.01.002.
3. Rosen LS (2005) VEGF-targeted therapy: therapeutic potential and
recent advances. Oncologist 10: 382-391. doi:10.1634/theoncologist.
10-6-382. PubMed: 15967832.
4. Brewer GJ (2005) Copper lowering therapy with tetrathiomolybdate as
an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5:
195-202. doi:10.2174/1568009053765807. PubMed: 15892619.
5. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM et al. (2002)
Copper deficiency induced by tetrathiomolybdate suppresses tumor
growth and angiogenesis. Cancer Res 62: 4854-4859. PubMed:
12208730.
6. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD et al. (2007)
Tetrathiomolybdate promotes tumor necrosis and prevents distant
metastases by suppressing angiogenesis in head and neck cancer. Mol
Cancer Ther 6: 1039-1045. doi:10.1158/1535-7163.MCT-06-0524.
PubMed: 17363496.
7. Montenegro MA, Sanchez Negrette M, Gimeno EJ, Borda JT (2002)
Effects of high molybdenum intake on 1,2-dimethylhydrazine-induced
intestinal tumors in rats. Biocell : official journal of the Sociedades
Latinoamericanas de Microscopia Electronica et al 26: 339-345.
8. Cox C, Merajver SD, Yoo S, Dick RD, Brewer GJ et al. (2003) Inhibition
of the growth of squamous cell carcinoma by tetrathiomolybdate-
induced copper suppression in a murine model. Arch Otolaryngol Head
Neck Surg 129: 781-785. doi:10.1001/archotol.129.7.781. PubMed:
12874082.
9. Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF et al. (2009) A
pilot trial of the anti-angiogenic copper lowering agent
tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and
leucovorin for metastatic colorectal cancer. Invest New Drugs 27:
159-165. doi:10.1007/s10637-008-9165-9. PubMed: 18712502.
10. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK et al. (2003)
Phase II trial of tetrathiomolybdate in patients with advanced kidney
cancer. Clin Cancer Res Off J Am Assoc Cancer Res 9: 1666-1672.
PubMed: 12738719.
11. Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S (2008) A phase II
trial of tetrathiomolybdate after surgery for malignant mesothelioma:
final results. Ann Thorac Surg 86: 383-389; discussion 390 doi:
10.1016/j.athoracsur.2008.03.016. PubMed: 18640301.
12. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP et al. (1990)
Inhibition of angiogenesis and tumor growth in the brain. Suppression
of endothelial cell turnover by penicillamine and the depletion of
copper, an angiogenic cofactor. Am J Pathol 137: 1121-1142. PubMed:
1700617.
13. Jain RK (2005) Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy. Science 307: 58-62. doi:10.1126/
science.1104819. PubMed: 15637262.
14. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel
normalization for cancer and other angiogenic diseases. Nat Rev Drug
Discov 10: 417-427. doi:10.1038/nrd3455. PubMed: 21629292.
15. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M et al. (2008)
Vascular normalization in Rgs5-deficient tumours promotes immune
destruction. Nature 453: 410-414. doi:10.1038/nature06868. PubMed:
18418378.
16. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma.
Lancet 366: 397-408. doi:10.1016/S0140-6736(05)67025-0. PubMed:
16054941.
17. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P et al. (2003)
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate
destruction of tumor cells and tumor-associated vasculature: a novel
mechanism for IL-2. J Immunol 171: 5051-5063. PubMed: 14607902.
18. Klein D, Lichtmannegger J, Heinzmann U, Summer KH (2000)
Dissolution of copper-rich granules in hepatic lysosomes by D-
penicillamine prevents the development of fulminant hepatitis in Long-
Evans cinnamon rats. J Hepatol 32: 193-201. doi:10.1016/
S0168-8278(00)80063-X. PubMed: 10707858.
19. Goodman VL, Brewer GJ, Merajver SD (2004) Copper deficiency as an
anti-cancer strategy. Endocr Relat Cancer 11: 255-263. doi:10.1677/
erc.0.0110255. PubMed: 15163301.
20. Siegemund R, Lössner J, Günther K, Kühn HJ, Bachmann H (1991)
Mode of action of triethylenetetramine dihydrochloride on copper
metabolism in Wilson’s disease. Acta Neurol Scand 83: 364-366. doi:
10.1111/j.1600-0404.1991.tb03964.x. PubMed: 1887758.
21. Hou G, Dick R, Zeng C, Brewer GJ (2006) Comparison of lowering
copper levels with tetrathiomolybdate and zinc on mouse tumor and
doxorubicin models. Transl Res 148: 309-314. doi:10.1016/j.trsl.
2006.06.005. PubMed: 17162252.
22. Hou G, Dick R, Zeng C, Brewer GJ (2007) Antitumor and
antiinflammatory effects of tetrathiotungstate in comparison with
tetrathiomolybdate. Transl Res J Lab Clin Med 149: 260-264. doi:
10.1016/j.trsl.2006.12.003. PubMed: 17466925.
23. Prewett M, Huber J, Li Y, Santiago A, O’Connor W et al. (1999)
Antivascular endothelial growth factor receptor (fetal liver kinase 1)
monoclonal antibody inhibits tumor angiogenesis and growth of several
mouse and human tumors. Cancer Res 59: 5209-5218. PubMed:
10537299.
24. Crowe A, Morgan EH (1996) Iron and copper interact during their
uptake and deposition in the brain and other organs of developing rats
exposed to dietary excess of the two metals. J Nutr 126: 183-194.
PubMed: 8558300.
25. Zowczak M, Iskra M, Paszkowski J, Mańczak M, Torliński L et al.
(2001) Oxidase activity of ceruloplasmin and concentrations of copper
and zinc in serum of cancer patients. J Trace Elem Med Biol 15:
193-196. doi:10.1016/S0946-672X(01)80066-3. PubMed: 11787988.
26. Wei H, Frei B, Beckman JS, Zhang WJ (2011) Copper Chelation by
Tetrathiomolybdate Inhibits Lipopolysaccharide-Induced Inflammatory
Responses in Vivo. Am J Physiol Heart Circ Physiol, 301: H712–20.
PubMed: 21724870.
27. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M et al. (2000)
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper,
antiangiogenic agent: Phase I study. Clin Cancer Res 6: 1-10. PubMed:
10656425.
28. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R et al. (2001)
Evaluation of angiogenesis in non-small cell lung cancer: comparison
between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer
Res Off J Am Assoc Cancer Res 7: 3410-3415. PubMed: 11705856.
29. Youdim MB, Grünblatt E, Mandel S (2007) The copper chelator, D-
penicillamine, does not attenuate MPTP induced dopamine depletion in
mice. J Neural Transm 114: 205-209. doi:10.1007/s00702-006-0499-1.
PubMed: 16736232.
30. Brewer GJ (2005) Anticopper therapy against cancer and diseases of
inflammation and fibrosis. Drug Discov Today 10: 1103-1109. doi:
10.1016/S1359-6446(05)03541-5. PubMed: 16182195.
31. Deering TB, Dickson ER, Fleming CR, Geall MG, McCall JT et al.
(1977) Effect of D-penicillamine on copper retention in patients with
primary billiary cirrhosis. Gastroenterology 72: 1208-1212. PubMed:
870369.
32. Yoshii J, Yoshiji H, Kuriyama S, Ikenaka Y, Noguchi R et al. (2001) The
copper-chelating agent, trientine, suppresses tumor development and
angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer
94: 768-773. doi:10.1002/ijc.1537. PubMed: 11745476.
33. Kadowaki S, Endoh D, Okui T, Hayashi M (2009) Trientine, a copper-
chelating agent, induced apoptosis in murine fibrosarcoma cells by
activation of the p38 MAPK pathway. J Vet Med Sci 71: 1541-1544. doi:
10.1292/jvms.001541. PubMed: 19959910.
34. Hayashi M, Nishiya H, Chiba T, Endoh D, Kon Y et al. (2007) Trientine,
a copper-chelating agent, induced apoptosis in murine fibrosarcoma
cells in vivo and in vitro. J Vet Med Sci 69: 137-142. doi:10.1292/jvms.
69.137. PubMed: 17339757.
35. Khan G, Merajver S (2009) Copper chelation in cancer therapy using
tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs
18: 541-548. doi:10.1517/13543780902845622. PubMed: 19335282.
36. Brewer GJ (2009) The use of copper-lowering therapy with
tetrathiomolybdate in medicine. Expert Opin Investig Drugs 18: 89-97.
doi:10.1517/13543780802621859. PubMed: 19053885.
Lowering Cu Slows Tumors and Normalizes Vessels
PLOS ONE | www.plosone.org 13 August 2013 | Volume 8 | Issue 8 | e73684
37. Goodman VL, Brewer GJ, Merajver SD (2005) Control of copper status
for cancer therapy. Curr Cancer Drug Targets 5: 543-549. doi:
10.2174/156800905774574066. PubMed: 16305350.
38. Nasulewicz A, Mazur A, Opolski A (2004) Role of copper in tumour
angiogenesis--clinical implications. J Trace Elem Med Biol Organ Soc
Miner Trace Elem 18: 1-8. doi:10.1016/j.jtemb.2004.02.004. PubMed:
15487757.
39. Brewer GJ (2001) Copper control as an antiangiogenic anticancer
therapy: lessons from treating Wilson’s disease. Exp Biol Med 226:
665-673. PubMed: 11444102.
40. Richards MP (1999) Zinc, copper, and iron metabolism during porcine
fetal development. Biol Trace Elem Res 69: 27-44. doi:10.1007/
BF02783913. PubMed: 10383097.
41. Lowndes SA, Harris AL (2005) The role of copper in tumour
angiogenesis. J Mammary Gland Biol Neoplasia 10: 299-310. doi:
10.1007/s10911-006-9003-7. PubMed: 16924372.
42. Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG (2002) Food
intake, water intake, and drinking spout side preference of 28 mouse
strains. Behav Genet 32: 435-443. doi:10.1023/A:1020884312053.
PubMed: 12467341.
43. Brem S (1999) Angiogenesis and Cancer Control: From Concept to
Therapeutic Trial. Cancer Contr J Moffitt Cancer Center 6: 436-458.
PubMed: 10758576.
44. Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ et al. (2006) Phase II
trial of copper depletion with tetrathiomolybdate as an antiangiogenesis
strategy in patients with hormone-refractory prostate cancer. Oncology
71: 168-175. doi:10.1159/000106066. PubMed: 17641535.
45. Schuschke DA, Reed MW, Saari JT, Olson MD, Ackermann DM et al.
(1992) Short-term dietary copper deficiency does not inhibit
angiogenesis in tumours implanted in striated muscle. Br J Cancer 66:
1059-1064. doi:10.1038/bjc.1992.410. PubMed: 1280989.
46. Omari KM, Dorovini-Zis K (2003) CD40 expressed by human brain
endothelial cells regulates CD4+ T cell adhesion to endothelium. J
Neuroimmunol 134: 166-178. doi:10.1016/S0165-5728(02)00423-X.
PubMed: 12507785.
47. Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hämmerling GJ et al.
(2008) Vascular targeting of anti-CD40 antibodies and IL-2 into
autochthonous tumors enhances immunotherapy in mice. J Clin Invest
118: 1691-1699. doi:10.1172/JCI33201. PubMed: 18398504.
48. Liu L, Abken H, Pföhler C, Rappl G, Tilgen W et al. (2000)
Accumulation of CD4+CD7- T cells in inflammatory skin lesions:
evidence for preferential adhesion to vascular endothelial cells. Clin
Exp Immunol 121: 94-99. doi:10.1046/j.1365-2249.2000.01260.x.
PubMed: 10886244.
Lowering Cu Slows Tumors and Normalizes Vessels
PLOS ONE | www.plosone.org 14 August 2013 | Volume 8 | Issue 8 | e73684
